Scientists may have underestimated how much genes contribute to Alzheimer's risk - News-Medical

For years, the scientific community has operated under a specific mathematical assumption: that common genetic variants account for only about 5% of the liability for Alzheimer’s disease. It was a figure that suggested while genetics played a role, the environment and lifestyle factors held the lion’s share of the influence. But that assumption may have been a significant underestimate.

A massive international study published in the journal Nature suggests the genetic contribution is much heavier than once believed. By analyzing genetic data from nearly 2.8 million people, researchers found that in certain European-ancestry cohorts, the estimated heritability on the liability scale was actually 16%. This isn’t just a minor statistical correction; it is a fundamental shift in how we view the biological “blueprint” of the world’s most prevalent form of dementia.

As reported by News-Medical, this research, which synthesized data from 30 different cohorts, identifies 127 different genetic risk loci—including 48 that have never been identified before. This discovery moves the conversation away from a narrow focus on amyloid-beta aggregates and toward a much more complex web of immune system activity and cellular dysregulation.

The shift from amyloid to immune response

Current disease-modifying treatments have focused heavily on clearing amyloid-beta from the brain, yet these interventions have often struggled to deliver significant clinical relief for patients. The new data suggests the reason for this limited success might be that the “engine” of the disease isn’t just protein buildup, but a breakdown in how the brain’s immune cells manage itself.

The study’s findings point toward a central role for microglia—the specialized immune cells of the brain. The researchers found that genes associated with Alzheimer’s risk are heavily enriched in these cells, particularly those involved in inflammatory states and phagocytosis (the process by which cells “eat” or clear out debris). This suggests that the brain’s own immune response might be a primary driver of the disease, rather than just a secondary reaction to plaque formation.

While the study also found links to neuronal populations—specifically small neuropeptide-expressing neurons and certain inhibitory interneurons—the connection to microglia remained the most statistically significant. This distinction is vital. It raises a difficult question for researchers: Are the changes we see in neurons a cause of Alzheimer’s, or are they simply the wreckage left behind by an overactive or malfunctioning immune system?

Identifying new targets for the next generation of drugs

Finding new genetic “loci” is only useful if it leads to better medicine. The investigators didn’t just map the risk; they prioritized specific genes that could serve as potential therapeutic targets. Among the most promising candidates identified are RRM2B, SYK, KEAP1, CACNA1S, and AXL.

The implications for drug development are immediate, though they come with necessary caveats. For instance, the genes SYK and AXL are already known to be involved in how the immune system responds to amyloid-beta. Interestingly, the study noted that while some of these genes, like RRM2B and KEAP1, have shown promise in earlier experimental research, interventions involving CACNA1S and AXL did not improve outcomes in previous human or mouse studies. It is important to note that these genes were not tested as actual treatments in this specific study; they are simply the most logical places for the next wave of clinical trials to look.

This targeted approach could lead to a more “precision medicine” model for dementia, where treatments are designed to modulate specific biological pathways—like lipid binding or immune activation—rather than taking a one-size-fits-all approach to protein clearance.

Metric/Finding	Previous/Standard Estimates	New Study Findings
Common genetic variant liability	Approximately 5%	Up to 16% (in European cohorts)
Total identified risk loci	~80 loci	127 loci (including 48 new)
Primary biological focus	Amyloid-beta aggregates	Microglial and neuronal dysregulation

The looming crisis of genetic inequity

Despite the breakthrough, there is a significant shadow hanging over these findings: the lack of diversity in genetic data. The study’s effective sample size was heavily skewed, with European ancestry accounting for approximately 91% of the participants. While the researchers did include data from African, East Asian, South Asian, and admixed American populations, the precision of the results for these groups was markedly lower.

If we develop risk-prediction tools—known as Polygenic Risk Scores (PRS)—based primarily on European DNA, we risk creating a tiered system of healthcare. In the UK Biobank, for example, individuals in the top decile of genetic risk were seven times more likely to develop Alzheimer’s than those in the bottom decile. However, because the prediction models are less accurate for non-European populations, those communities may be left without the benefit of early warning or personalized prevention strategies.

The data shows that the estimated heritability in East Asian cohorts was 13%, and in African cohorts, it was 10%, but the researchers noted that these differences were not yet statistically established due to the sample sizes. Without larger, more diverse datasets, the promise of genetic risk assessment will remain a privilege of specific demographics rather than a universal tool for all.

The path forward requires more than just better math; it requires a concerted effort to ensure that the genetic map of Alzheimer’s disease reflects the actual diversity of the human population.

Keep reading